Used in research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), an enzyme primarily expressed in the brain, particularly in the striatum. It is investigated for its potential in treating neurological and psychiatric disorders such as schizophrenia, Huntington's disease, and other conditions involving dysregulation of the dopaminergic and glutamatergic systems. Due to its ability to modulate intracellular signaling pathways by increasing cyclic adenosine monophosphate (cAMP) levels, it serves as a tool compound in preclinical studies to understand PDE10A function and evaluate therapeutic strategies targeting cognitive and motor symptoms. Not intended for human use outside of experimental settings.